Member Info for mazik

Short termers out...we are blue and moving north to the first target of 30p

Putting cash generated during high commodity prices to work into maximising recovery from our existing assets and developing near term incremental production opportunities as well as growing our nascent geothermal business into a material enterprise..Short termers out expecting going north to 50p pluss market cap way too cheap IMO

IGAS share of the Year...£1 plus

Glad topped up in the afternoon..27084 just before the movement...good luck all... Thanks Swissy for sharing info of Geni background and expectation..the last RNS made me confident for long term..Licence for California will open door for all US states will definately rerate and mcap could multibag..imo

Few shares...difficult to buy.

Top up but difficult to buy now...few shares in my opinion going north to 20p

Doug Fleming sums up for us to notice "Doug Fleming added:
"I am very pleased to be joining IGas and bringing my experience to the team. It is an exciting time for the company - the company's cash generative oil and gas production gives it an excellent platform from which to drive its growing geothermal business." Keeping mine and adding more shares, future is bright at Igas IMO

Deltalo thank u for sharing your knowledge on geothermal in UK and SSE the provider..wow have topup more tomorrow...could reach last year high

Stew agree with u 30p plus..few shares, it was well oversold.

It was oversold, back to 30p plus

JV news to be announced next week I Hope, multibagger on news.. best of luck

Worst luck with Val since its inception...forget RR lucky owning an old MERC.

Consolidating at the moment...topup and fully loaded

Value and trend is your friend...few shares Fda approval is a fact

Wall Street investors will pile in....definately 50p sooner than later.

Heart disease is the leading cause of death for men, women, and people of most racial and ethnic groups in the United States.1 One person dies every 34 seconds in the United States from cardiovascular disease.1 About 697,000 people in the United States died from heart disease in 2020 - which is one in every five deaths.1,2 Heart disease cost the United States about $229 billion each year from 2017 to 2018.3 This includes the cost of health care services, medicines, and lost productivity due to death. This could be rerated to 50p IMO

Topped again another 10k....feel this will be 20p and at close friday 50p imo...holding for long term

This will carry on north with rerating to 20p... and could be the share of 2023....

Difficult to buy...managed to get just 20k shares....only 90 million shares...Enormous potential..

Agree with u Mister Positive...